CY1116865T1 - Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης - Google Patents

Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης

Info

Publication number
CY1116865T1
CY1116865T1 CY20151100963T CY151100963T CY1116865T1 CY 1116865 T1 CY1116865 T1 CY 1116865T1 CY 20151100963 T CY20151100963 T CY 20151100963T CY 151100963 T CY151100963 T CY 151100963T CY 1116865 T1 CY1116865 T1 CY 1116865T1
Authority
CY
Cyprus
Prior art keywords
lower alkyl
hydrogen
cycloalkyl
substituted
divenzo
Prior art date
Application number
CY20151100963T
Other languages
English (en)
Inventor
Alexander Flohr
Guido Galley
Roland Jakob-Roetne
Eric Argirios Kitas
Jens-Uwe Peters
Wolfgang Wostl
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1116865T1 publication Critical patent/CY1116865T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/121,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ενώσεις του γενικού τύπου (I), όπου η R1 είναι -(CHR')q –αρύλιο ή -(CHR')q-ετεροαρύλιο, τα οποία είναι μη υποκατεστημένα ή μονο-, δι- ή τρι-υποκατεστημένα με κατώτερο αλκύλιο, κατώτερο άλκοξυ, CF3 ή αλογόνο, ή είναι κατώτερο αλκύλιο, κατώτερο αλκενύλιο, -(CH2)n-Si(CH3)3, -(CΗ2)n-O-κατώτερο αλκύλιο, -(CH2)n-S-κατώτερο αλκύλιο, -(CΗ2)q-κυκλοαλκύλιο, -(CH2)n-[CH(OH)]m-(CF2)p-CHqF(3-q), ή είναι -(CH2)n-CR2-CF3, όπου οι δύο ρίζες R μαζί με το άτομο άνθρακα σχηματίζουν δακτύλιο κυκλοαλκυλίου· η R' είναι υδρογόνο ή κατώτερο αλκύλιο· n είναι 1, 2 ή 3· m είναι 0 ή 1· p είναι 0,1, 2, 3,4, 5 ή 6· q είναι 0, 1, 2 ή 3· η R2 είναι υδρογόνο ή κατώτερο αλκύλιο· η R3 είναι υδρογόνο, κατώτερο αλκύλιο, -CH2CF2CF3, CH2CF3, (CH2)2CF3, CF3, CHF2, CH2F, ή είναι αρύλιο, προαιρετικά μονο-, δι- ή τρι-υποκατεστημένο με αλογόνο, ή είναι (CH2)nNR5R6, όπου οι R5 και R6 είναι ανεξαρτήτως μεταξύ των υδρογόνο ή κατώτερο αλκύλιο· η R4 είναι μία από τις ακόλουθες ομάδες όπου η R7 είναι υδρογόνο, κατώτερο αλκύλιο, -(CH2)n-CF3 ή -(CΗ2)n-κυκλοαλκύλιο· η R8 είναι υδρογόνο, κατώτερο αλκύλιο, -C(O)-φαινύλιο, -C(O)-κατώτερο αλκύλιο, -C(O)O-(CΗ2)n-κυκλοαλκύλιο, -C(O)O-(CΗ2)n-κατώτερο αλκύλιο, -C(O)ΝΗ-(CΗ2)n-κατώτερο αλκύλιο ή -C(O)ΝΗ-(CH2)n-κυκλο-αλκύλιο· η R9 είναι υδρογόνο, κατώτερο αλκύλιο, -(CH2)n-κυκλοαλκύλιο ή -(CH2)n-CF3· και με φαρμακευτικώς κατάλληλα άλατα προσθήκης οξέος, οπτικώς καθαρά εναντιομερή, ρακεμικά μίγματα ή διαστερεομερικά μίγματα αυτών για τη θεραπευτική αγωγή της νόσου του Alzheimer.
CY20151100963T 2003-10-06 2015-10-29 Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης CY1116865T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03022650 2003-10-06
EP04787028.2A EP1673347B1 (en) 2003-10-06 2004-09-27 Substituted dibenzo-azepine and benzo-diazepine derivatives useful as gamma-secretase inhibitors

Publications (1)

Publication Number Publication Date
CY1116865T1 true CY1116865T1 (el) 2017-04-05

Family

ID=34384575

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100963T CY1116865T1 (el) 2003-10-06 2015-10-29 Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης

Country Status (27)

Country Link
US (1) US7166587B2 (el)
EP (1) EP1673347B1 (el)
JP (1) JP4503607B2 (el)
KR (2) KR100884872B1 (el)
CN (1) CN1894217B (el)
AR (1) AR045859A1 (el)
AU (1) AU2004283803B2 (el)
BR (1) BRPI0415070B8 (el)
CA (1) CA2541470C (el)
CO (1) CO5690560A2 (el)
CY (1) CY1116865T1 (el)
DK (1) DK1673347T3 (el)
ES (1) ES2548720T3 (el)
HR (1) HRP20151197T1 (el)
HU (1) HUE025548T2 (el)
IL (1) IL174513A (el)
MX (1) MXPA06003870A (el)
MY (1) MY143797A (el)
NO (1) NO20061469L (el)
NZ (1) NZ546036A (el)
PL (1) PL1673347T3 (el)
PT (1) PT1673347E (el)
RU (1) RU2356895C2 (el)
SI (1) SI1673347T1 (el)
TW (1) TWI293627B (el)
WO (1) WO2005040126A1 (el)
ZA (1) ZA200602802B (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7211573B2 (en) 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
JP5030781B2 (ja) * 2005-09-05 2012-09-19 良明 木曽 βセクレターゼ阻害剤
CN101410378B (zh) * 2006-03-27 2012-12-05 霍夫曼-拉罗奇有限公司 作为γ分泌酶抑制剂的丙二酰胺衍生物
KR101096476B1 (ko) 2006-09-20 2011-12-20 에프. 호프만-라 로슈 아게 4-옥소-2,3,4,5-테트라히드로-벤조[b][1,4]디아제핀 유도체
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
JP5523107B2 (ja) 2006-11-30 2014-06-18 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
CN101622232A (zh) 2007-02-02 2010-01-06 弗·哈夫曼-拉罗切有限公司 6-氧代-6,7-二氢-5h-二苯并[b,d]氮杂䓬-7-基衍生物
KR20090115951A (ko) 2007-03-01 2009-11-10 프로비오드룩 아게 글루타미닐 사이클라제 저해제의 신규 용도
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7579464B2 (en) * 2007-05-25 2009-08-25 Hoffmann-La Roche Inc. Process for preparation of enantiomerically pure compounds
CN102695546B (zh) 2009-09-11 2014-09-10 前体生物药物股份公司 作为谷氨酰胺酰环化酶抑制剂的杂环衍生物
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
US20130102538A1 (en) * 2010-05-05 2013-04-25 Amicus Therapeutics, Inc. Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JO3148B1 (ar) 2011-07-27 2017-09-20 Lilly Co Eli مركب مثبط لإشارات مسار notch
NZ741553A (en) 2015-10-30 2019-08-30 Inception 3 Inc Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス, インコーポレイテッド 蝸牛シナプス障害を処置する方法
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN112236147A (zh) * 2018-05-15 2021-01-15 百时美施贵宝公司 包含双氟烷基-1,4-苯并二氮杂*酮化合物的组合物和其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778005B2 (en) * 1998-12-24 2004-11-11 Bristol-Myers Squibb Pharma Company Succinoylamino benzodiazepines as inhibitors of Abeta protein production
CA2404273A1 (en) * 2000-04-11 2001-10-18 Bristol-Myers Squibb Pharma Company Substituted lactams as inhibitors of a.beta. protein production
CN1386118A (zh) * 2000-06-01 2002-12-18 布里斯托尔-迈尔斯斯奎布药品公司 作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
BRPI0407262A (pt) * 2003-02-04 2006-01-31 Hoffmann La Roche Derivados de malonamida como inibidores gama-secretase
KR20070087233A (ko) * 2003-09-09 2007-08-27 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체

Also Published As

Publication number Publication date
MY143797A (en) 2011-07-15
BRPI0415070B1 (pt) 2018-05-15
NO20061469L (no) 2006-06-26
AU2004283803B2 (en) 2010-06-24
KR20060085632A (ko) 2006-07-27
DK1673347T3 (en) 2015-10-12
NZ546036A (en) 2009-10-30
JP2007507447A (ja) 2007-03-29
RU2356895C2 (ru) 2009-05-27
MXPA06003870A (es) 2006-07-03
CA2541470C (en) 2011-11-29
PL1673347T3 (pl) 2016-01-29
AU2004283803A1 (en) 2005-05-06
ES2548720T3 (es) 2015-10-20
HUE025548T2 (en) 2016-02-29
ZA200602802B (en) 2007-09-26
CN1894217A (zh) 2007-01-10
CO5690560A2 (es) 2006-10-31
JP4503607B2 (ja) 2010-07-14
PT1673347E (pt) 2015-11-02
RU2006115165A (ru) 2007-11-20
CN1894217B (zh) 2011-09-21
IL174513A0 (en) 2006-08-01
IL174513A (en) 2011-12-29
KR100884872B1 (ko) 2009-02-23
WO2005040126A1 (en) 2005-05-06
BRPI0415070B8 (pt) 2021-05-25
KR20080016754A (ko) 2008-02-21
CA2541470A1 (en) 2005-05-06
HRP20151197T1 (hr) 2015-12-04
TWI293627B (en) 2008-02-21
SI1673347T1 (sl) 2015-10-30
EP1673347B1 (en) 2015-08-19
TW200526586A (en) 2005-08-16
AR045859A1 (es) 2005-11-16
US20050075327A1 (en) 2005-04-07
US7166587B2 (en) 2007-01-23
BRPI0415070A (pt) 2006-12-12
KR100867035B1 (ko) 2008-11-04
EP1673347A1 (en) 2006-06-28

Similar Documents

Publication Publication Date Title
CY1116865T1 (el) Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης
CY1109225T1 (el) ΠΑΡΑΓΩΓΑ ΜΗΛΟΝΑΜΙΔΙΟΥ ΤΑ ΟΠΟΙΑ ΠΑΡΕΜΠΟΔΙΖΟΥΝ ΤΗ ΔΡΑΣΗ ΤΗΣ γ-ΣΕΚΡΕΤΑΣΗΣ
RU2500680C2 (ru) Новые замещенные пиридин-2-оны и пиридазин-3-оны
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
PE20090042A1 (es) Analogos de ciclopamina
EA200802389A1 (ru) Азиридинилэпотилоновые соединения
NO20085160L (no) Nye glucokinaseaktivatorer og deres anvendelse
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
RU2007147340A (ru) Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний
CY1110960T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ 4-(2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ)ΦΑΙΝΟΛΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΤΟΥ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΥΠΟΔΟΧΕΑ
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
TW200635585A (en) Monocyclic substituted methanones
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR058347A1 (es) Entidades quimias composiciones y metodos
AR060623A1 (es) Compuestos derivados de 2-azetidinona y un metodo de preparacion
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
RU2014145819A (ru) Бициклическое соединение
JP2010527915A5 (el)
AR077819A1 (es) Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip)
AR042002A1 (es) Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central.
PE20030705A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
HUP0303801A2 (hu) Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2009518397A5 (el)
AR041376A1 (es) Piperazinas sustituidas por heterociclos para el tratamiento de la esquizofrenia
DK1583752T3 (da) Cykliseringsfremgangsmåde til substituerede benzothiazolderivater